All In Biotech

Drug Trial Radar · NCT02030821

TXA vs. Amicar in Total Knee and Hip Arthroplasty

TXA (Tranexamic Acid) vs. Amicar (Aminocaproic Acid) in Total Knee and Hip Arthroplasty- Effectiveness, Safety, and Cost Analysis

Last checked: Nov 20, 2026Latest source record: Dec 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

246

Actual

Start

Jan 2015

Primary completion

Nov 12, 2017

Study completion Nov 12, 2017

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the relative effectiveness of two drug agents, Tranexamic acid (TXA) and aminocaproic acid (Amicar), that act through a similar mechanism of action. These agents are used to decrease blood loss that is a result of major surgery, like total joint arthroplasty. A secondary goal will be investigate the cost-analysis of total hospitalization. Both TXA and Amicar are both currently used in the care of patients undergoing total joint arthroplasty. Subjects will be randomly assigned to the TXA or Amicar arm. All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization stay. Our Hypothesis is that TXA and Amicar will have similar effectiveness in preventing intraoperative blood loss and the need for transfusion post-op than Amicar. A detailed cost analysis will show that the overall cost of performing the operative procedure, including transfusions, OR time, and total costs associated with admission cost will be more decreased with Amicar as compared to TXA.

Conditions

  • Blood Loss
  • Hip Arthritis
  • Knee Arthritis

Interventions

  • AmicarDrug

    Subjects randomized to receive Amicar will receive this during surgical intervention

  • TXADrug

    Subjects randomized to receive TXA will receive this during surgical intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge)Time frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
  2. Number of TransfusionsTime frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days
  3. Difference in Preoperative and Lowest Postoperative HemoglobinTime frame: Participants will be followed for the duration of hospital stay, an expected average of 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.